Anwar R Padhani

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5186626/anwar-r-padhani-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

268 78 21,193 139 h-index g-index citations papers 6.8 6.81 24,540 295 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
268	Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis <i>European Radiology</i> , 2022 , 32, 2135	8	O
267	Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling <i>European Urology</i> , 2022 ,	10.2	
266	Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score <i>Radiology</i> , 2022 , 212252	20.5	2
265	Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis <i>European Urology Open Science</i> , 2022 , 40, 95-103	0.9	0
264	A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 596-611	6.2	19
263	Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study. <i>JAMA Oncology</i> , 2021 , 7, 395-402	13.4	27
262	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021 , 4, 714-730	6.7	3
261	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. <i>European Radiology</i> , 2021 , 31, 9567-9578	8	8
260	Effects of Sex and Age on Fat Fraction, Diffusion-Weighted Image Signal Intensity and Apparent Diffusion Coefficient in the Bone Marrow of Asymptomatic Individuals: A Cross-Sectional Whole-Body MRI Study. <i>Diagnostics</i> , 2021 , 11,	3.8	2
259	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. <i>Radiology</i> , 2021 , 299, 494-507	20.5	4
258	Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question. Journal of Magnetic Resonance Imaging, 2021 , 53, 13-22	5.6	4
257	Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. <i>BJU International</i> , 2021 , 127, 175-178	5.6	7
256	Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. <i>BJU International</i> , 2021 , 127, 304-306	5.6	15
255	PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. <i>American Journal of Roentgenology</i> , 2021 , 216, 3-19	5.4	19
254	Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. <i>European Urology Oncology</i> , 2021 ,	6.7	14
253	Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. <i>European Radiology</i> , 2021 , 31, 6116-6124	8	7
252	Semi-Automated Segmentation of Bone Metastases from Whole-Body MRI: Reproducibility of Apparent Diffusion Coefficient Measurements. <i>Diagnostics</i> , 2021 , 11,	3.8	3

(2020-2021)

251	Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use. <i>Radiologia Medica</i> , 2021 , 126, 1434-1450	6.5	13
250	Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e299-e305	3.3	O
249	Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis. <i>Abdominal Radiology</i> , 2020 , 45, 4012-4022	3	5
248	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. <i>European Radiology</i> , 2020 , 30, 5404-5416	8	80
247	Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. <i>Cancer Imaging</i> , 2020 , 20, 34	5.6	14
246	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. <i>European Urology Oncology</i> , 2020 , 3, 145-167	6.7	37
245	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1963-1996	2.2	51
244	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
243	Population-based prostate cancer screening using a prospective, blinded, paired screen-positive comparison of PSA and fast MRI: The IP1-PROSTAGRAM study <i>Journal of Clinical Oncology</i> , 2020 , 38, 5513-5513	2.2	2
242	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists training 2020 , 30, 5404		1
241	Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging. <i>Seminars in Musculoskeletal Radiology</i> , 2020 , 24, 726-750	1.8	3
240	Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis. <i>European Urology Oncology</i> , 2020 , 3, 32-41	6.7	22
239	Developments in MRI-targeted prostate biopsy. Current Opinion in Urology, 2020, 30, 1-8	2.8	5
238	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy. <i>European Urology</i> , 2020 , 77, 481-490	10.2	19
237	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. <i>European Urology</i> , 2020 , 77, 469-480	10.2	20
236	Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. <i>Radiology</i> , 2020 , 297, 622-629	20.5	10
235	Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>European Urology</i> , 2020 , 78, 633-636	10.2	4
234	Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 83	51.1	77

233	Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. <i>Clinical Radiology</i> , 2020 , 75, 950-956	2.9	3
232	Rethinking prostate cancer screening: could MRI be an alternative screening test?. <i>Nature Reviews Urology</i> , 2020 , 17, 526-539	5.5	5
231	Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. <i>Cancer Imaging</i> , 2020 , 20, 77	5.6	6
230	What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. <i>British Journal of Radiology</i> , 2020 , 93, 20200562	3.4	12
229	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition. <i>European Urology</i> , 2020 , 77, 457-468	10.2	34
228	Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?. <i>World Journal of Urology</i> , 2020 , 38, 531-545	4	14
227	Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions. <i>Journal of Magnetic Resonance Imaging</i> , 2020 ,	5.6	6
226	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-nalle Men: The Next Step in Magnetic Resonance Imaging Accessibility. <i>European Urology</i> , 2019 , 76, 574-581	10.2	61
225	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. <i>Radiology</i> , 2019 , 292, 464-474	20.5	84
224	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine,the</i> , 2019 , 7, 523-532	35.1	30
223	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 529-537	18.8	28
222	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. <i>European Urology</i> , 2019 , 76, 340-351	10.2	576
221	How clinical imaging can assess cancer biology. <i>Insights Into Imaging</i> , 2019 , 10, 28	5.6	36
220	Adding Colour to the Grey Zone of Advanced Prostate Cancer. European Urology Focus, 2019, 5, 123-12-	45.1	3
219	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. <i>European Urology</i> , 2019 , 75, 385-396	10.2	121
218	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , 2019 , 292, 273-286	20.5	24
217	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. <i>Health Technology Assessment</i> , 2019 , 23, 1-270	4.4	17
216	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). <i>Radiology</i> , 2019 , 291, 5-13	20.5	117

(2017-2019)

215	A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach. <i>Investigative Radiology</i> , 2019 , 54, 437-447	10.1	17
214	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-nalle Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter	10.2	293
213	Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. <i>Radiologia Medica</i> , 2019 , 124, 218-233	6.5	31
212	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2019 , 30, e3	10.3	12
211	Advanced Imaging Techniques in Evaluation of Colorectal Cancer. <i>Radiographics</i> , 2018 , 38, 740-765	5.4	32
210	National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. <i>BJU International</i> , 2018 , 122, 13-25	5.6	78
209	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
208	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. <i>British Journal of Radiology</i> , 2018 , 91, 20170577	3.4	46
207	Patterns of disease progression in patients with local and metastatic breast cancer as evaluated by whole-body magnetic resonance imaging. <i>Breast</i> , 2018 , 40, 82-84	3.6	2
206	Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC) <i>Journal of Clinical Oncology</i> , 2018 , 36, 5024-5024	2.2	2
205	Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 155-163.e6	3.3	13
204	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology, The</i> , 2018 , 19, e696-e708	21.7	59
203	Whole-Body Magnetic Resonance Imaging in Oncology: Uses and Indications. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018 , 26, 495-507	1.6	19
202	Metastasis Reporting and Data System for Prostate Cancer in Practice. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018 , 26, 527-542	1.6	6
201	Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK. <i>BMJ Open</i> , 2018 , 8, e018499	3	11
200	Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. <i>European Urology Oncology</i> , 2018 , 1, 208-214	6.7	17
199	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017 , 71, 81-92	10.2	150
198	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017 , 71, 648-655	10.2	132

197	Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. <i>Targeted Oncology</i> , 2017 , 12, 229-234	5	2
196	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L). <i>BMC Cancer</i> , 2017 , 17, 299	4.8	18
195	The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2017 , 77, 109	9 ⁷ 1 ⁵ 16	28
194	One-Step Systemic Staging for Patients with Breast Cancer 2017 , 265-276		
193	Rationale for Modernising Imaging in Advanced Prostate Cancer. European Urology Focus, 2017, 3, 223-2	23391	46
192	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 169-186	19.4	532
191	Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. <i>Clinical and Translational Imaging</i> , 2016 , 4, 439-447	2	41
190	Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. <i>Journal of Magnetic Resonance Imaging</i> , 2016 , 44, 521-40	5.6	123
189	Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?. <i>British Journal of Radiology</i> , 2016 , 89, 20150961	3.4	12
188	Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. <i>Prostate</i> , 2016 , 76, 1024-33	4.2	34
187	Therapy Monitoring with Functional and Molecular MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016 , 24, 261-288	1.6	24
186	Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?. <i>Diagnostic and Interventional Radiology</i> , 2016 , 22, 75-89	3.2	31
185	Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. <i>PLoS ONE</i> , 2016 , 11, e0153840	3.7	30
184	Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40. <i>European Urology</i> , 2016 , 70, e137-e138	10.2	12
183	Advanced imaging of colorectal cancer: From anatomy to molecular imaging. <i>Insights Into Imaging</i> , 2016 , 7, 285-309	5.6	14
182	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. <i>EBioMedicine</i> , 2016 , 10, 109-	1 <mark>8</mark> .8	23
181	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015 , 26, 1589-60	4 ^{10.3}	220
180	Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?. <i>Annals of Oncology</i> . 2015 , 26, 1048-1057	10.3	38

(2013-2015)

179	Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors. <i>Oncologist</i> , 2015 , 20, 368-9	5.7	5
178	Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. <i>Journal of Magnetic Resonance Imaging</i> , 2015 , 42, 1190-202	5.6	207
177	Imaging of Tumor Angiogenesis for RadiologistsPart 1: Biological and Technical Basis. <i>Current Problems in Diagnostic Radiology</i> , 2015 , 44, 407-24	1.6	39
176	Imaging of Tumor Angiogenesis for RadiologistsPart 2: Clinical Utility. <i>Current Problems in Diagnostic Radiology</i> , 2015 , 44, 425-36	1.6	14
175	Will Magnetic Resonance Imaging-guided Biopsy Replace Systematic Biopsy?. <i>European Urology Focus</i> , 2015 , 1, 152-155	5.1	2
174	Magnetic Resonance Imaging, Digital Mammography, and Sonography: Tumor Characteristics and Tumor Biology in Primary Setting. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 15-2	o ^{4.8}	3
173	Robot-assisted radical prostatectomy: Multiparametric MR imaging-directed intraoperative frozen-section analysis to reduce the rate of positive surgical margins. <i>Radiology</i> , 2015 , 274, 434-44	20.5	37
172	Therapy monitoring of skeletal metastases with whole-body diffusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2014 , 39, 1049-78	5.6	79
171	Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: are signal intensity-time curves adequate?. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 335-43	4.4	26
170	Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. <i>PLoS ONE</i> , 2014 , 9, e91779	3.7	87
169	New Therapies and Functional-Molecular Imaging 2014 , 77-96		
168	Optimal source distribution for focal boosts using high dose rate (HDR) brachytherapy alone in prostate cancer. <i>Radiotherapy and Oncology</i> , 2014 , 113, 121-5	5.3	11
167	Apparent diffusion coefficient measurements as very early predictive markers of response to chemotherapy in hepatic metastasis: a preliminary investigation of reproducibility and diagnostic value. <i>Journal of Magnetic Resonance Imaging</i> , 2014 , 40, 448-56	5.6	22
166	Whole-body MRI and diffusion MRI. Cancer Imaging, 2014, 14,	5.6	2
165	Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. <i>European Radiology</i> , 2013 , 23, 3466-76	8	29
164	Prostate MRI: who, when, and how? Report from a UK consensus meeting. <i>Clinical Radiology</i> , 2013 , 68, 1016-23	2.9	76
163	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 281-4	2.8	25
162	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013 , 24, 1141-62	10.3	109

161	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. <i>Journal of Magnetic Resonance Imaging</i> , 2013 ,	5.6	106
160	37, 48-58 CT perfusion in oncologic imaging: a useful tool?. <i>American Journal of Roentgenology</i> , 2013 , 200, 8-19	5.4	125
159	The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2013 , 17,	4.4	85
158	vii-xix, 1-281 Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI. <i>American Journal of Roentgenology</i> , 2013 , 200, 163-70	5.4	110
157	Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. <i>American Journal of Roentgenology</i> , 2012 , 199, 252-62	5.4	130
156	Tumor response assessments with diffusion and perfusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 35, 745-63	5.6	131
155	Diffusion tensor imaging of the anal canal at 3 tesla: feasibility and reproducibility of anisotropy measures. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 35, 820-6	5.6	14
154	Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. <i>European Radiology</i> , 2012 , 22, 1451-64	8	124
153	Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2012 , 156, 557	4.5	8
152	Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 3428-39	12.9	141
151	Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2012 , 23, 231-237	10.3	51
150	Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 1415-25	12.9	62
149	Diffusion MR imaging for monitoring of treatment response. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2011 , 19, 181-209	1.6	105
148	Novel oncologic drugs: what they do and how they affect images. <i>Radiographics</i> , 2011 , 31, 2059-91	5.4	62
147	Integrating multiparametric prostate MRI into clinical practice. <i>Cancer Imaging</i> , 2011 , 11 Spec No A, S27	-3 .76	21
146	Bony metastases: assessing response to therapy with whole-body diffusion MRI. <i>Cancer Imaging</i> , 2011 , 11 Spec No A, S129-45	5.6	49
145	Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. <i>BJU International</i> , 2011 , 108, 1716-22	5.6	36
144	Diffusion magnetic resonance imaging in cancer patient management. <i>Seminars in Radiation Oncology</i> , 2011 , 21, 119-40	5.5	39

143	Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. <i>European Urology</i> , 2011 , 59, 477-94	10.2	537
142	Vascular characterisation of triple negative breast carcinomas using dynamic MRI. <i>European Radiology</i> , 2011 , 21, 1364-73	8	62
141	Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review. <i>Skeletal Radiology</i> , 2011 , 40, 665-81	2.7	167
140	Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 721-7	4	46
139	Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. <i>Radiology</i> , 2011 , 260, 68-78	20.5	89
138	Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. <i>Radiology</i> , 2011 , 261, 700-18	20.5	245
137	Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 103-7	4.8	29
136	Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 71-4	4.8	40
135	Multiparametric imaging of tumor response to therapy. <i>Radiology</i> , 2010 , 256, 348-64	20.5	178
134	The role of functional imaging in colorectal cancer. <i>American Journal of Roentgenology</i> , 2010 , 195, 54-6	65.4	50
		- J . T	
133	Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. <i>Radiology</i> , 2010 , 257, 643-52	20.5	45
133			45
	susceptibility-weighted MR imaging before and during chemotherapy. <i>Radiology</i> , 2010 , 257, 643-52 Science to practice: what does MR oxygenation imaging tell us about human breast cancer	20.5	45
132	susceptibility-weighted MR imaging before and during chemotherapy. <i>Radiology</i> , 2010 , 257, 643-52 Science to practice: what does MR oxygenation imaging tell us about human breast cancer hypoxia?. <i>Radiology</i> , 2010 , 254, 1-3 Functional magnetic resonance imaging of the liver: parametric assessments beyond morphology.	20.5	45
132	susceptibility-weighted MR imaging before and during chemotherapy. <i>Radiology</i> , 2010 , 257, 643-52 Science to practice: what does MR oxygenation imaging tell us about human breast cancer hypoxia?. <i>Radiology</i> , 2010 , 254, 1-3 Functional magnetic resonance imaging of the liver: parametric assessments beyond morphology. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2010 , 18, 565-85, xii Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision	20.5	45 32 10
132 131 130	Science to practice: what does MR oxygenation imaging tell us about human breast cancer hypoxia? Radiology, 2010, 254, 1-3 Functional magnetic resonance imaging of the liver: parametric assessments beyond morphology. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 565-85, xii Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 Suppl 1, S164-82 Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI)	20.5 20.5 1.6 8.8	45 32 10 61
132 131 130	Science to practice: what does MR oxygenation imaging tell us about human breast cancer hypoxia? Radiology, 2010, 254, 1-3 Functional magnetic resonance imaging of the liver: parametric assessments beyond morphology. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 565-85, xii Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 Suppl 1, S164-82 Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Targeted Oncology, 2010, 5, 39-52 Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. Journal of	20.5 20.5 1.6 8.8	45 32 10 61 88

MRI to Assess Vascular Disruptive Agents **2010**, 137-163

124	Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. <i>British Journal of Cancer</i> , 2009 , 100, 644-8	8.7	51
123	A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. <i>Clinical Cancer Research</i> , 2009 , 15, 4484-92	12.9	66
122	Quantitative analysis of dynamic contrast-enhanced MR images based on Bayesian P-splines. <i>IEEE Transactions on Medical Imaging</i> , 2009 , 28, 789-98	11.7	26
121	A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study. <i>Magnetic Resonance in Medicine</i> , 2009 , 61, 163-74	4.4	27
120	Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. <i>Journal of Biomechanics</i> , 2009 , 42, 712-21	2.9	58
119	Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. <i>European Radiology</i> , 2009 , 19, 2728-38	8	141
118	Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review. <i>Radiographics</i> , 2009 , 29, 759-74; discussion 774-8	5.4	139
117	Dynamic optical breast imaging: a novel technique to detect and characterize tumor vessels. <i>European Journal of Radiology</i> , 2009 , 69, 43-9	4.7	29
116	Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. <i>Neoplasia</i> , 2009 , 11, 102-25	6.4	1462
115	Diffusion-Weighted Imaging 2009 , 685-706		
114	Technology insight: water diffusion MRIa potential new biomarker of response to cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 220-33		279
113	Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 6580-9	12.9	222
112	Coupled modeling of blood perfusion in intravascular, interstitial spaces in tumor microvasculature. <i>Journal of Biomechanics</i> , 2008 , 41, 996-1004	2.9	31
111	Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. <i>European Radiology</i> , 2008 , 18, 1414-21	8	34
110	Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2007 , 25, 796-805	5.6	43
109	Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 417-24	4	71
108	Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 1375-8	30 ⁴	68

107	Imaging oxygenation of human tumours. European Radiology, 2007, 17, 861-72	8	270
106	Numerical simulation of blood flow and interstitial fluid pressure in solid tumor microcirculation based on tumor-induced angiogenesis. <i>Acta Mechanica Sinica/Lixue Xuebao</i> , 2007 , 23, 477-483	2	14
105	2007,		2
104	18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22the NCRI Testis Tumour Clinical Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3090-5	2.2	93
103	Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. <i>American Journal of Roentgenology</i> , 2007 , 188, 442-51	5.4	112
102	Dynamic contrast enhanced MRI in prostate cancer. European Journal of Radiology, 2007, 63, 335-50	4.7	178
101	Functional imaging of colorectal cancer angiogenesis. <i>Lancet Oncology, The</i> , 2007 , 8, 245-55	21.7	76
100	Imaging tumor angiogenesis: functional assessment using MDCT or MRI?. <i>Abdominal Imaging</i> , 2006 , 31, 194-9		64
99	Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. <i>British Journal of Surgery</i> , 2006 , 93, 992-1000	5.3	59
98	Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2006 , 24, 1316-25	5.6	29
97	Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. <i>Radiographics</i> , 2006 , 26, 621-32	5.4	73
96	Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study. <i>Radiology</i> , 2006 , 239, 677-85	20.5	24
95	Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage?. <i>American Journal of Roentgenology</i> , 2006 , 187, 1079-84	5.4	68
94	Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. <i>Radiology</i> , 2006 , 239, 361-74	20.5	209
93	Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. <i>Radiology</i> , 2006 , 239, 547-53	20.5	123
92	The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. <i>British Journal of Cancer</i> , 2006 , 95, 1683-8	8.7	32
91	Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. <i>British Journal of Cancer</i> , 2006 , 95, 801	-107	94
90	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. <i>International Journal of Radiation Biology</i> , 2006 , 82, 699-757	2.9	506

89	Bayesian methods for pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. <i>IEEE Transactions on Medical Imaging</i> , 2006 , 25, 1627-36	11.7	61
88	Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. <i>British Journal of Radiology</i> , 2006 , 79, 633-5	3.4	113
87	USPIO Lenhanced rectal cancer specimen MRI: how well does it correlate with node identification at histopathology?. <i>Colorectal Disease</i> , 2006 , 8, 721-721	2.1	4
86	A test of performance of breast MRI interpretation in a multicentre screening study. <i>Magnetic Resonance Imaging</i> , 2006 , 24, 917-29	3.3	13
85	A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2006 , 24, 3015-3015	2.2	10
84	PET imaging of tumour hypoxia. <i>Cancer Imaging</i> , 2006 , 6, S117-21	5.6	4
83	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). <i>Lancet, The</i> , 2005 , 365, 1769-78	40	786
82	Dynamic Contrast-Enhanced MRI of Prostate Cancer 2005 , 191-213		1
81	Dynamic Magnetic Resonance Imaging in Breast Cancer 2005 , 145-173		2
80	Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 1309-15	4	116
79	Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. <i>Clinical Oncology</i> , 2005 , 17, 167-71	2.8	15
78	The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. <i>British Journal of Cancer</i> , 2005 , 92, 1599-610	o ^{8.7}	443
77	Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. <i>Abdominal Imaging</i> , 2005 , 30, 324-41		108
76	Imaging tumour angiogenesis. <i>Cancer Imaging</i> , 2005 , 5, 131-8	5.6	54
75	Imaging breast cancer response during neoadjuvant systemic therapy. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 893-905	3.5	18
74	MRI in the detection and management of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 239-52	3.5	19
73	Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. <i>Radiology</i> , 2005 , 236, 779-88	20.5	90
72	Statistical analysis of pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. <i>Lecture Notes in Computer Science</i> , 2005 , 8, 886-93	0.9	9

71	Angiogenesis imaging in the management of prostate cancer. <i>Nature Reviews Urology</i> , 2005 , 2, 596-607		50
70	Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. <i>British Journal of Cancer</i> , 2005 , 93, 979-85	8.7	30
69	Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. <i>IEEE Engineering in Medicine and Biology Magazine</i> , 2004 , 23, 65-83		133
68	Perfusion MR imaging of extracranial tumor angiogenesis. <i>Topics in Magnetic Resonance Imaging</i> , 2004 , 15, 41-57	2.3	61
67	Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 582-582	2.2	8
66	MRI for assessing antivascular cancer treatments. <i>British Journal of Radiology</i> , 2003 , 76 Spec No 1, S60-8	89.4	118
65	Recent advances in oncological imaging. <i>Clinical Medicine</i> , 2003 , 3, 318-22	1.9	2
64	Dynamic MRI of breast hardness following radiation treatment. <i>Journal of Magnetic Resonance Imaging</i> , 2003 , 17, 427-34	5.6	13
63	Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. <i>British Journal of Radiology</i> , 2003 , 76 Spec No 1, S87-91	3.4	109
62	The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. <i>Lung Cancer</i> , 2003 , 42, 283-90	5.9	67
61	Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2831-42	2.2	304
60	Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. <i>Journal of Magnetic Resonance Imaging</i> , 2002 , 16, 407-22	5.6	367
59	Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. <i>NMR in Biomedicine</i> , 2002 , 15, 132-42	4.4	297
58	Reproducibility of quantitative dynamic MRI of normal human tissues. <i>NMR in Biomedicine</i> , 2002 , 15, 143-53	4.4	169
57	Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. <i>NMR in Biomedicine</i> , 2002 , 15, 174-83	4.4	60
56	Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. <i>NMR in Biomedicine</i> , 2002 , 15, 154-63	4.4	234
55	Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. <i>British Journal of Cancer</i> , 2002 , 86, 336-41	8.7	20
54	Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3826-40) ^{2.2}	139

53	A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. <i>Annals of Oncology</i> , 2002 , 13, 1763-70	10.3	7
52	Magnetic resonance imaging of induration in the irradiated breast. <i>Radiotherapy and Oncology</i> , 2002 , 64, 157-62	5.3	17
51	Diffusion MRI for prediction of response of rectal cancer to chemoradiation. <i>Lancet, The</i> , 2002 , 360, 30	7-& O	392
50	Initial observations on the effect of irradiation on the liver-specific uptake of Levovist. <i>European Journal of Radiology</i> , 2002 , 41, 192-9	4.7	30
49	Functional MRI for anticancer therapy assessment. European Journal of Cancer, 2002, 38, 2116-27	7.5	86
48	Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. <i>British Journal of Surgery</i> , 2001 , 88, 1628-36	5.3	197
47	BOLD MRI of human tumor oxygenation during carbogen breathing. <i>Journal of Magnetic Resonance Imaging</i> , 2001 , 14, 156-63	5.6	160
46	Problem in diagnostic imaging: Mediastinal venous anomalies. <i>Clinical Anatomy</i> , 2001 , 14, 218-26	2.5	6
45	The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. British Journal of Cancer, 2001 , 85, 1624-6	8.7	26
44	Challenges for imaging angiogenesis. <i>British Journal of Radiology</i> , 2001 , 74, 886-90	3.4	56
43	The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. <i>British Journal of Radiology</i> , 2001 , 74, 983-6	3.4	193
42	Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. <i>Bone Marrow Transplantation</i> , 2001 , 27, 967-71	4.4	41
41	Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. <i>Radiology</i> , 2001 , 218, 365-74	20.5	130
40	Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. <i>Clinical Radiology</i> , 2001 , 56, 607-20	2.9	197
39	Dynamic contrast-enhanced MR imaging. <i>Cancer Imaging</i> , 2000 , 1, 52-63	5.6	6
38	Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 649-56	4	195
37	Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. <i>Magnetic Resonance Imaging</i> , 2000 , 18, 765-76	3.3	92
36	FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. <i>British Journal of Cancer</i> , 2000 , 83, 287-93	8.7	96

35	Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques. <i>Radiology</i> , 2000 , 214, 837-42	20.5	68
34	Commentary. Are current tumour response criteria relevant for the 21st century?. <i>British Journal of Radiology</i> , 2000 , 73, 1031-3	3.4	30
33	Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. <i>Clinical Radiology</i> , 2000 , 55, 99-109	2.9	279
32	In vivo monitoring of tumor angiogenesis with MR imaging. <i>Academic Radiology</i> , 2000 , 7, 812-23	4.3	104
31	Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging. <i>American Journal of Roentgenology</i> , 1999 , 173, 173-8	5.4	19
30	Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. <i>British Journal of Radiology</i> , 1999 , 72, 590-7	3.4	64
29	Dynamic contrast-enhanced MRI studies in human tumours. <i>British Journal of Radiology</i> , 1999 , 72, 427-3	313.4	26
28	Advances in imaging of colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999 , 30, 189-99	7	5
27	Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 525-33	4	238
26	Spiral CT: thoracic applications. European Journal of Radiology, 1998, 28, 2-17	4.7	8
25	Magnetic resonance imaging of prostate cancer: comparison of image quality using endorectal and pelvic phased array coils. <i>Clinical Radiology</i> , 1998 , 53, 673-81	2.9	61
24	Metastatic cardiac osteosarcomaimaging features. British Journal of Radiology, 1998, 71, 336-9	3.4	7
23	MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. <i>Radiographics</i> , 1998 , 18, 497-506	5.4	54
22	Mediastinal venous anomalies: potential pitfalls in cancer diagnosis. <i>British Journal of Radiology</i> , 1998 , 71, 792-8	3.4	9
21	Radiation induced liver injury detected by particulate reticuloendothelial contrast agent. <i>British Journal of Radiology</i> , 1998 , 71, 1089-92	3.4	10
20	Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. <i>Radiotherapy and Oncology</i> , 1997 , 42, 1-15	5.3	206
19	A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. <i>Annals of Oncology</i> , 1997 , 8, 995-1001	10.3	107
18	Evaluation by magnetic resonance imaging of the inferior vena cava in patients with non-seminomatous germ cell tumours of the testis metastatic to the retroperitoneum. <i>BJU International</i> , 1997 , 79, 942-51	5.6	12

17	Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. <i>Journal of Magnetic Resonance Imaging</i> , 1997 , 7, 564-74	5.6	181
16	Problem in diagnostic imaging: behind the left renal vein. <i>Clinical Anatomy</i> , 1997 , 10, 349-52	2.5	7
15	The value of immediate cytologic evaluation for needle aspiration lung biopsy. <i>Investigative Radiology</i> , 1997 , 32, 453-8	10.1	27
14	Pulmonary sarcoidosis mimicking cryptogenic fibrosing alveolitis on CT. <i>Clinical Radiology</i> , 1996 , 51, 807	7- <u>1</u> .6	60
13	Case report: Phrenic artery injurya rare complication of percutaneous needle lung biopsy. <i>British Journal of Radiology</i> , 1996 , 69, 356-8	3.4	3
12	Multiplanar display of spiral CT data of the pulmonary hila in patients with lung cancer. Preliminary observations. <i>Clinical Imaging</i> , 1995 , 19, 252-7	2.7	15
11	Eye and testicular pain after administration of gadopentetate dimeglumine. <i>American Journal of Roentgenology</i> , 1995 , 165, 484-5	5.4	2
10	Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). <i>European Journal of Cancer</i> , 1995 , 31A, 2209-14	7.5	15
9	The value of immediate cytological evaluation for needle aspiration lung biopsy. <i>Clinical Radiology</i> , 1995 , 50, 350-1	2.9	4
8	CT features of pulmonary nocardiosis. <i>Journal of Computer Assisted Tomography</i> , 1995 , 19, 726-32	2.2	33
7	Computed tomography in abdominal trauma: an audit of usage and image quality. <i>British Journal of Radiology</i> , 1992 , 65, 397-402	3.4	7
6	Chest radiography for general practitioners: scope for change?. Clinical Radiology, 1992, 46, 51-4	2.9	6
5	Computed tomography in blunt abdominal trauma: an analysis of clinical management and radiological findings. <i>Clinical Radiology</i> , 1992 , 46, 304-10	2.9	8
4	Surgical restraint in the management of liver trauma. <i>British Journal of Surgery</i> , 1991 , 78, 1071-5	5.3	26
3	T1-W DCE-MRI: T1-Weighted Dynamic Contrast-Enhanced MRI341-364		18
2	Diffusion-weighted MRI of female pelvic tumors119-143		1

Localization of Cancer within the Prostate: Dynamic Contrast-Enhanced MRI55-65